Biological agents targeting beyond TNF-alpha

Rashmi Sharma, Chaman Lal Sharma¹, Annil Mahajan²

Biological agents represent an important addition to the therapies for immuno-inflammatory conditions and have a great impact on the disease course and quality of life of these patients. However, recent reports of serious infections like tuberculosis, demyelinating and neurodegenerative diseases, pancytopenia, cardiovascular diseases, etc. after anti-TNF therapy raised questions on their safety. Hence, focus is shifted towards drugs targeting cytokine checkpoints in the inflammatory cascades beyond TNF-α. Existing therapeutic targets include the biological agents acting as antagonists of various inflammatory cytokines (Anakinra, Tocilizumab, Atlizumab) and modulators of CD80 or CD86-CD28 co-stimulatory signal (Abatacept), CD2 receptors on T-cells (Alefacept), CD11a, subunit of leukocyte function-associated antigen 1 (Efalizumab), vitronectin receptor and CD20 antigen on pre-B, immature and mature B cells (Rituximab). With the introduction of these novel molecules the future for immunomodulatory intervention in rheumatology, asthma, crohn’s disease, septic shock etc. looks very promising. These novel therapeutic agents could truly give a new hope to the clinician to modify the disease and achieve tangible improvements in the lives of the patients.

Key words: Biological agents; cytokines; CD20 antigen; rheumatology; T-cells

Biologics are proteins produced by living organisms to target specific sites of the inflammatory cascade, including antibodies against cell surface markers, cytokines and adhesion molecules.¹ The biological agents represent an important addition to the therapies for immuno-inflammatory conditions and have a great impact on the disease course and quality of life of these patients. However, recent reports of reactivation of TB (tuberculosis) after anti-TNF therapy raised question on their safety. TNF-α plays an important role in the host defense against mycobacterial infection, particularly in granuloma formation and inhibition of mycobacterial dissemination.² FDA recommended a black box for TB on the product labeling of infliximab.³ Other serious infections reported with etanercept include sepsis secondary to Listeria monocytogenes and Histoplasma capsulatum.² Severe disseminated opportunistic infections have been reported in the HIV positive patients.² SLE syndrome, demyelinating diseases, neurodegenerative diseases, pancytopenia, cardiovascular diseases, new onset or flare-up of chronic iridocyclitis, thyroid cancer, hypoglossal nerve paralysis, severe cytomegalovirus pulmonary infection, reactivation of Crohn’s disease etc. are the other important adverse effects reported with anti-TNF-α therapy.²⁴,⁵

However, the success of TNF blockade clearly indicates that there are various checkpoints in cytokine-mediated inflammation. Hence, the identification and development of molecules targeting such critical ‘regulatory cytokines’ (beyond TNF) may have the potential to become a novel

From:
Department of Pharmacology and Therapeutics, ¹Indian-III Hospital, UN Mission Congo (Monuc), Armed Medical Corps- India, ²Department of General Medicine, Govt. Medical College, Jammu (J and K) India

Correspondence:
Dr. Rashmi Sharma, Postgraduate Department of Pharmacology and Therapeutics, Govt. Medical College, Jammu (J and K) -180 001, India.
E-mail: rashmichams@yahoo.com

Free full text available from www.ijccm.org
addition in the armamentarium against various immuno-inflammatory conditions. Hence, in the present article we are reviewing some of these non-TNF-α biologicals.

**Search Methodology:** Prominent rheumatology and general/internal medicine journals (MEDLINE, EMBASE, PUBMED between 2000 and 2006) were searched for review papers and clinical trials published on drugs targeting inflammatory cytokines other than TNF-α. All the data was collected and important evidences regarding pharmacology and uses of non-TNF-α biologicals were summarized in the present article.

**Cytokine networks and their therapeutic targets in clinical practice** [6-8]

Cytokines are soluble (glyco) proteins, non-immunoglobulin in nature, released by living cells of the host, which act non-enzymatically in picomolar to nanomolar concentrations through specific receptors to regulate host cell function. Cytokines are pleiotropic in their biological activities and play pivotal roles in a variety of responses, including the immune response, hematopoiesis, neurogenesis, embryogenesis and oncogenesis. The main types of cytokines are lymphokines, interleukins, monokines, tumor necrosis factors (TNF), interferons, colony-stimulating factors, transforming growth factors, peptide growth factors, heat shock and other stress proteins. Cytokines have been classified on the basis of their biological responses into pro- or anti-inflammatory cytokines, depending on their effects on immunocytes [Table 1]. TNF, interleukin (IL)-1, IL-6, IL-7, IL-8, IL-12, IL-15, IL-17, IL-18, IL-23, lymphotoxin, macrophage migration inhibitory factor, resistin, interferon-γ, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, fibroblast growth factor and vascular endothelial growth factor are the proinflammatory cytokines. Whereas, IL-1Ra, IL-18 binding protein, IL-10, transforming growth factors, IL-11, IL-13, osteoprotegerin, adiponectin, etc are the anti-inflammatory cytokines. IL-22, oncostatin M etc are equivocal. Cytokines can be released not only by immune cells but also by host tissue cells. Various molecules (anakinra, tocilizumab, atlimuzumab, abatacept, alefacept, efalizumab, rituximab) targeting these cytokines are in clinical development.

Existing therapeutic targets include the biologicals acting as antagonists of various inflammatory cytokines

**Table 1: Cytokines and their role** [6-8,43,44]

| Cytokine | Function |
|----------|----------|
| IL-1     | Activates APC and CD4+ lymphocytes; affects the differentiation of the B and T-Cells and other immunocompetent cells, takes part in the regulation of productions of other cytokines and GMCSF. |
| IL-2     | Stimulates the proliferation and activation of B-Cells and T-Cells. |
| IL-4     | Plays a role in the differentiation of TH2, in allergic responses and in the switching of antibody types. |
| IL-5     | Stimulates the production and maturation of eosinophils during inflammation. |
| IL-6     | Acts as a chemotactic factor that attracts neutrophils, basophils and T-Cells to sites of inflammation. |
| IL-8     | A critical linker between the innate immunity and adaptive immunity, capable of TH1 differentiation and IFN-Gamma release by T-Cells and NK Cells. |
| IL-10    | Acts to repress secretion of pro-inflammatory cytokines. |
| IL-3     | Potent activator of the hemopoietic cells. It stimulates NK-Cells and acts as a synergist with IL-4 during the induction of CD4+ lymphocyte activation process. |
| IL-7     | Induces apoptosis of tumor cells and causes differentiation of cells from a subgroup of acute myeloblastic leukemia. |
| IL-9     | Stimulates the excretion of IL-2, IL-4, IL-6, IL-11 and cytotoxicity of T-Killers and NK-Cells, inducing apoptosis. |
| IL-11    | Regulates the functions of B-Cells and T-Cells, induces various killer cells' activities and acts as an autocrine factor for the proliferation of megacaryocytes. |
| IL-13    | Inhibits the proliferation of leukemic pro-B-Cells. |
| IL-14    | BCGF and the hyper production of this interleukin enables the progression of NHL-B. |
| IL-15    | Increases the antitumor activities of T-Killers and NK-Cells, and the production of cytokines CD4+ lymphocytes. |
| IL-17    | Takes part in the regulation of many cytokines and can reinforce the antibody dependant tumor cell destructions. |
| IL-18    | Synergist with IL-12, especially in the induction of IFN-Gamma production and inhibition of angiogenesis. |
| IL-19    | Regulates the functions of macrophages and suppresses the activities of TH1 and TH2. |
| IL-21    | Promotes a high production of T-Cells, fast growth and maturation of NK-Cells and B-Cells population. |
| IL-22    | Similar to IL-10, but does not prohibit the production of pro-inflammatory cytokines through monocytes. |
| TNFs     | Activates macrophages, inhibits apoptosis of neutrophils and eosinophils, induces vascular endothelial cells to bind to phagocytes, induce proliferation of NK-Cells and stimulate innate and adaptive immune responses. |
| Resistin | Stabilize TNF and IL-6 release. |
| Adiponectin | Modulates TNF-induced inflammation. |

APC = Antigen presenting cell, GMCSF = Granulocyte-Macrophage Colony-Stimulating Factor, TH2 = T Helper Type-2, TH1 = T Helper Type-1, NK = Natural killer, INF = Interferon, IL = Interleukins, BCGF = B-Cell Growth Factor, NHL-B = B-cell type non Hodgkin's lymphoma.
and modulators of CD80 or CD86-CD28 co-stimulatory signal, CD2 receptors on T-cells, CD11a, sub-unit of leukocyte function-associated antigen 1 (LeFA-1), vitronectin receptor and CD20 antigen on pre-B, immature and mature B cells [Table 2].

Anakinra: It is recombinant form of nonglycosylated human IL-1 receptor antagonist expressed in Escherichia coli. Natural IL-1 receptor antagonist is produced by macrophages and activated monocytes in response to various inflammatory stimuli. Anakinra competitively binds to both type-I and type-II IL-1 receptors, at least partially blocking cellular responses mediated by IL-1-α and IL-1-β. It has a binding affinity similar to IL-1, but it lacks IL-1 agonist activity. Its daily dose is 100 mg/day subcutaneously (SC). Prior hypersensitivity to anakinra or E-coli derived proteins and active infection are the important contraindications with the use of anakinra.

Common adverse reactions reported with it are headache, nausea, diarrhea, sinusitis, erythema, ecchymosis, pruritis at injection site, influenza like symptoms, production of anti-anakinra antibodies, neutropenia, cardiopulmonary arrest and serious infections. Live vaccines should not be administered concurrently with anakinra. It should be used with caution in patients with neutropenia, immuno-suppression, moderate to severe renal impairment, pregnancy or breastfeeding period, and concomitant use of TNF blocking agents.

Clinical Trials: In a dosage ranging multi-center placebo controlled trial patients of Rheumatic arthritis (RA) on 1-2 mg/kg/day of anakinra with MTX 15-25 mg/week achieved more ACR (American College of Rheumatology preliminary criteria for improvement) 20 response than MTX alone at 12 weeks.[12] In another study with 100 mg/day of anakinra in combination with

Table 2: Biologics agents beyond anti-TNF-therapy [2-12,18-35]

| Drugs | Binding target | Dose | Adverse drug reaction | FDA approval |
|-------|----------------|------|-----------------------|--------------|
| Anakinra | IL-1 receptor | 1-2 mg/kg/day S/C. | Neutropenia, cardio-pulmonary arrest, influenza like symptoms, production of anti-anakinra antibodies and serious infections. | RA(2001), Studied in Asp, psoriasis and PA. |
| Attilizumab: | IL-6 receptor | 2-8 mg/kg I.V. every 2 wkly | Increased blood cholesterol levels. | -- |
| Abatacept: | Selectively modulates the CD80 or CD86-CD28 co-stimulatory signal required for full T-cell activation | 10 mg/kg I.V. every 2 wkly for 3 doses followed by 4 wkly. | -- | RA(2005) Studied in Asp, psoriasis and PA, CD-UC. |
| Rituaximab: | CD 20 antigen on B cells | ---- | Antibody levels against HSV 1/2 and VZV are not significantly affected Cytotoxic effect is selective for the activated memory T-cells. reduces total lymphocyte count and CD4+ and CD8+ cell counts. | Cancers, B-cell NHL(2001), RA(march 2006). Studied in Asp, psoriasis, PA, Psoriasis(jan 2003), |
| Alefacept | LFA-3 portion of alefacept binds to CD2 receptors on T-cells, IgG1 portion of alefacept binds to FcIR receptor on natural killer cells to induce T-cell apoptosis. | 10-15 mg IM wkly or 7.5 mg IV wkly for 12 wks. | -- | Psoriasis(2003) |
| Efalizumab | It interferes with the interaction between LeFα-1 and ICAM-1, a cell surface molecule expressed by APCs. | 1 mg/kg (max 200mg) wkly S.C. for 12wks | -- | Early stages of study in RA. |
| Vitaxin | Antagonizes vitronectin receptors involved in osteoclast mediated bone resorption, angiogenesis and macrophage dependent inflammation. | ---- | Acute flu-like symptoms, exacerbation of psoriasis on discontinuation, autoimmune hemolytic anemia, thrombocytopenia | --- |
MTX showed more efficacy in retarding radiographic progression than MTX alone.\textsuperscript{13} In a two-year prospective, in part retrospective, cohort study drug survival was 78\%, 54\%, and 14\% after 3, 6 and 24 months, respectively.\textsuperscript{14} However, National institute of clinical excellence of the united kingdom recommended its use in patients who are not responding to anti-TNF\(\alpha\) therapy alone or in patients with juvenile idiopathic arthritis.\textsuperscript{12,16}

In a clinical trial on 419 patients with moderate-to-severe active RA, who were receiving MTX for six consecutive months, the ACR20 responses at week 12 in the 5 active treatment (0.04, 0.1, 0.4, 1.0, or 2.0 mg/kg of anakinra) plus MTX groups demonstrated a statistically significant (\(P = 0.001\)) dose-response relationship compared with the ACR20 response in the placebo plus MTX group.\textsuperscript{16} In another trial 218 patients received subcutaneous injections of anakinra (30, 75, or 150 mg) once daily.\textsuperscript{17} The ACR20 response was 51\% at week 24 and 46\% at week 48 and this effect was consistent across all dose groups. Anakinra was well-tolerated for 76 weeks.\textsuperscript{17} Role of anakinra in chronic infantile neurological cutaneous and articular (CINCA) syndrome with a novel missense mutation in exon 4 of the CIAS1 gene (unresponsive to several treatments including prednisolone, immunosuppressants, DMARDs and TNF-blocker infliximab) has been documented.\textsuperscript{18} Anakinra, has a positive impact on both function and quality of life of the patients with RA.\textsuperscript{19} However, further clinical studies are needed to establish the additive benefits of the combination of TNF-\(\alpha\) blockade plus IL-1 receptor antagonism in RA.

**Abatacept:**\textsuperscript{20} It is a recombinant fusion protein comprising of the extra-cellular domain of human CTLA4 (cytotoxic T-lymphocyte antigen 4) and a fragment of the Fc domain of human IgG1, which has been modified to prevent complement fixation. It modulates the CD80 or CD86-CD28 co-stimulatory signal required for full T-cell activation. It is given in a dose of 10 mg/kg by IV infusion (three doses at the interval of two weeks, followed by infusion after every four weeks). Clinical Trials: In a Phase IIb multi-center international study in RA patients with inadequate response to MTX, ACR 20 response was achieved in 60\%, 41.9\% and 35.3\% patients with abatacept in a dose of 10 mg/kg, 2 mg/kg and placebo respectively after 6 months of the treatment as add on therapy to MTX.\textsuperscript{12} In a randomized double blind phase-III trial on patients with active RA refractory to anti-TNF-\(\alpha\) therapy, abatacept therapy for 6 months, in addition to at least one DMRDs (disease modifying antirheumatic drugs) produced ACR 20 response rate of 50.4\% as compare to 19.5\% in the placebo group (\(P<0.001\)).\textsuperscript{20} At six months, significantly more patients in the abatacept group than in the placebo group had a clinically meaningful improvement in physical function (47.3 percent vs 23.3 percent, \(P<0.001\)) with incidence of serious infections as 2.3\% in both the groups.\textsuperscript{20}

**Alefacept:**\textsuperscript{22} Alefacept is approved by US food and drug administration (FDA) in January 2003 for treatment in adult patients with moderate to severe chronic plaque psoriasis, who are candidates for systemic therapy or phototherapy. It is a bivalent recombinant fusion protein composed of the first extra-cellular domain lymphocyte function antigen 3 (LFA-3), fused to the hinge CH2 domain and CH3 domain of human IgG1. The LFA-3 portion of alefacept binds to CD2 receptors on T-cells, thereby blocking their natural interaction with LFA-3. The IgG1 portion of alefacept binds to Fc\(\gamma\)R on natural killer cells to induce T-cell apoptosis. Its dose is 10-15 mg IM (intramuscular) weekly or 7.5 mg IV (intravenous) weekly and a 12 week course is recommended.

Clinical Trials: In a double-blind RCT (randomized clinical trial) two 12-week courses of once-weekly IV alefacept 7.5 mg and placebo were given and patients were followed for 12 weeks after each course.\textsuperscript{21} Significantly more patients achieved greater reduction in the PASI (psoriasis area and severity index) than placebo both after first and second course of therapy.\textsuperscript{21} In an international, double-blind, placebo-controlled, RCT, 507 patients with chronic plaque psoriasis, were randomized to receive either 10 mg or 15 mg of alefacept once weekly for 12 weeks, followed by 12 weeks of observation.\textsuperscript{22} Thirty three percent and 28\% patients achieved 75\% reduction in PASI, two weeks after the last dose in 15 mg and 10 mg group respectively.\textsuperscript{22} The selective immunomodulatory effect of alefacept against potentially pathogenic T-cells is associated with maintenance of immune function to fight infection and response to vaccinations.\textsuperscript{23} It has been reported that it reduces total lymphocyte count and CD4\(^+\) and CD8\(^+\)cell counts. Hence, it is recommended to monitor CD4
counts weekly during therapy.

**Efalizumab**[2,3] It is approved by the US FDA in October 2003 for the treatment of psoriasis. It is a recombinant humanized monoclonal IgG1 antibody that binds to CD11a, subunit of leukocyte function-associated antigen 1 (LeFA-1). It interferes with the interaction between LeFA-1 and intercellular adhesion molecules (ICAM-1). By destabilizing the binding of APCs (antigen presenting cells) and T-cells, it reduces the efficiency of initial T-cell activation in lymph nodes. It interferes with the secondary activation of memory-effector T-cells in the target tissues. Its dose is 1 mg/kg (max 200mg) weekly, subcutaneous injection for 12 weeks, following a first conditioning dose of 0.7 mg/kg.

**Clinical trials:** In four large phase III studies in 2000 patients with moderate-to-severe chronic plaque psoriasis, efalizumab (1 mg/kg weekly) produced PASI 75 (>75% in reduction in baseline PASI score) in 27% of patients as compared to 4% patients in placebo group by week 12.[24-27] Continuation of therapy beyond 12 weeks increased the response rate further in efalizumab group. The relapse of psoriasis was evident after 2 months of discontinuation of therapy with rebound in approximately 5% of the patients, as defined by flaring>125% of baseline. Acute flu-like symptoms including headache, chills, fever, nausea and myalgia, an exacerbation of psoriasis after discontinuation of therapy, autoimmune hemolytic anemia, and thrombocytopenia are the common adverse events reported with its use.[2]

**Rituximab**[28-30] Rituximab is a specific mouse and human chimeric monoclonal antibody. This IgG1 has a long half-life of 76 to 200h and targets the CD20 antigen. The CD 20 antigen is present on pre-B, immature and mature B cells and is important for B-cell activation and proliferation. Binding of rituximab to CD 20 results in complement and antibody-dependent cyto-toxicity (apoptosis) of cells exhibiting this antigen. CD20 is not expressed on stem cells and plasma cells. Hence, depletion of the B-cell subpopulation is transient and does not affect immunoglobulin synthesis. Normal levels of total serum IgG are maintained and antibody levels against HSV (herpes simplex virus) 1/2 and VZV (varicella-zoster virus) are not significantly affected after rituximab treatment. Rituximab was the first therapeutic antibody approved for treating cancer. A supplemental Biological License Application (sBLA) was approved for it in April 2001, adding several new uses related to B-cell non-Hodgkin’s lymphoma. In 2006 rituximab in combination with MTX is approved for adult patients with moderately-to-severely active RA, who have had an inadequate response to one or more TNF antagonist therapies.

**Clinical Studies:** REFLEX, a Phase III clinical study of Rituximab in RA, met its primary endpoint and underpins the FDA’s approval.[29] It is also being evaluated in Phase II/III clinical trials for primary progressive and relapsed remitting multiple sclerosis, ANCA-associated vasculitis, systemic lupus erythematosus.[30] In an open label study Rituximab in combination with cyclophosphamide and prednisolone in five patients of refractory RA showed dramatic and sustained clinical improvement.[31] In a phase III multi-center double blind trial on 161 patients Rituximab in combination with MTX or cyclophosphamide showed more efficency than MTX alone.[31] Rituximab is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells.

**Atlizumab:**[12,32-35] It is a humanized anti-IL-6 receptor monoclonal antibody. It is efficacious in management of RA in a dose of 2-8 mg/kg/dose IV once every two weeks. It is a well-tolerated drug without any increase in antinuclear, anti-DNA or anti-atlizumab antibody. However, increase in blood cholesterol levels has been reported after its use for 24 weeks.

**Clinical Trial:**[12] In a phase I/II double blind RTC, atlizumab (5 mg/kg with MTX single dose) produced ACR20 response in 50% patients of RA as compare to placebo at week two. Improvement was maintained for eight weeks. In a multi-center double blind RCT, 78%, 57% and 11% RA patients achieved ACR20 response after three months of therapy with atlizumab 8 mg/kg, 4 mg/kg and placebo respectively.

**Tocilizumab:**[36,37] It is a recombinant humanized anti-IL-6R monoclonal antibody. Phase I and II studies of toclizumab in children with JIA (juvenile idiopathic arthritis), showed significant improvement in the typical symptoms of inflammation and laboratory abnormalities.

**AMG714** (previously HuMax-IL15):[38] IL-15 enhances
synovial T-cell proliferation and cytokine release and optimizes cognate interactions between T cells and macrophages. IL-15 induces synovial neutrophil activation, granule release from natural-killer cells, activation and migration of endothelial cells and prevents fibroblast apoptosis. AMG714, a fully human IgG1 monoclonal anti-IL-15 antibody, neutralizes soluble and membrane-bound IL-15 in vitro.

**Clinical Trials:** In a 12-week, dose-ascending, placebo-controlled study, AMG714 (0.5–8 mg/kg) produced significant improvement in disease activity in RA patients as compared to placebo. In another dose-finding study 60% of recipients receiving higher doses of AMG714 (160 mg or 240 mg) showed significant improvement as compared to lower doses. No significant alterations in the levels of circulating leukocyte subsets, including natural-killer cells and CD8+ memory T cells, were observed.

Alternate approaches to targeting IL-15 include the use of soluble IL-15Rα-derived proteins or antagonistic IL-15–Fc fusion proteins. CRB-15, an IL-15–Fc fusion protein, suppressed delayed-type hypersensitivity and allograft transplant rejection in rodent models.

Vitaxin (MEDI-522) is a humanized monoclonal IgG1 antibody that binds to a conformational epitope formed by both the integrin alpha V and beta 3 subunits. Alpha V and beta 3 integrin (vitronectin receptor) is expressed in low levels in most of the normal tissues (intestinal, vascular, and smooth muscle cells) and in high levels in bone, mid-menstrual cycle endometrium, placenta, inflammatory sites and invasive tumors. Vitronectin receptors have major role in osteoclast mediated bone resorption, angiogenesis and macrophage dependent inflammation. In RA, activated macrophages are increased in both subchondrial bone and inflamed synovial tissue; whereas, osteoclasts are increased in subchondrial bone at the site of bone erosion and resorption. Hence, antagonists of alpha V and beta 3

### Table 3: Clinical evidences showing efficacy of non-TNF biologic in immuno-inflammatory conditions

| Study                        | Disease          | Drugs                  | Duration | Results                                                                 |
|------------------------------|------------------|------------------------|----------|-------------------------------------------------------------------------|
| DRM RCT                      | RA               | Anakinra+MTX vs placebo+MTX | 12 wks   | >ACR 20 response in anakinra group than placebo group.                 |
| Cohort study                 | RA               | Anakinra               | 2 yr prospec. | Significant response at 3 months                                       |
| RCT                          | RA               | Anakinra+MTX vs placebo+MTX | 24 wks   | ACR response was dose dependent and >ACR 20 response in anakinra group than placebo group |
| MDBC group extension phase study | RA               | Anakinra vs placebo | 48wks | ACR 50 and ACR 70 responses are more in anakinra group than placebo group. |
| Case report                  | CINCA            | Anakinra               | -        | Improved condition in patient refractory to other DMRD and biologicals. |
| Phase II b multi-center international study | RA with inadequate response to MTX | Abatacept vs placebo. | 6 months | ACR 20 response was achieved in 60%, 41.9% and 35.3% patients with 10mg/kg, 2 mg/kg abatacept and placebo respectively. |
| Phase-III double blind RCT   | RA refractory to anti–TNF-α therapy | Abatacept + 1 DMRD | 6 months | ACR 20 response rate of 50.4% in abatacept group as compare to 19.5% in the placebo group (P<0.001); ACR 50 and ACR 70 responses were also higher in the abatacept group. |
| Double-blind RCT             | Psoriasis        | Alefacept vs placebo. | 12 wks   | Greater reduction in the PASI was achieved by alefacept group than placebo group ( p<0.001). |
| International, double-blind, placebo-controlled, RCT | Chronic plaque psoriasis | Alefacept 10 mg or 15 mg once wkly | 12 wks treatment and 12 wks follow-up, 12 wks treatment and 12 wks follow-up | In the 15 mg group, 33% patients achieved 75% reduction in PASI, 2 wks after the last dose and 28% patients achieved 75% reduction in PASI in the 10 mg group. |
| Four large phase III studies in 2000 patients | Chronic plaque psoriasis | Efalizumab vs placebo | >12 wks | 27% of patients in efalizumab group, achieved PASI 75 compared to 4% in placebo group by wk 12. |
| Phase I/II double blind RTC  | RA               | Atllizumab+MTX vs placebo | 8 wks   | 50% patients achieved ACR20 in atllizumab group at wk 2,but non in placebo group. |
| MDBC RCT                     | RA               | Atllizumab vs placebo | 3 months | 78%, 57% and 11% patients achieved ACR20 response in atllizumab 8mg/kg, 4 mg/kg and placebo group respectively. |
| Phase III MDBC               | RA               | Rituximab+MTX or CP vs MTX | ---     | More improvement in Rituximab group. |

**RCT** = randomized control trial, **RA** = rheumatoid arthritis, **PASI** = psoriasis area and severity index., **ACR** = American College of Rheumatology preliminary criteria for improvement, **CINCA** = chronic infantile neurological cutaneous and articular, **MTX** = methotrexate, **CP** = cyclophosphamide, **TNF** = tumour necrosis factor, **DMRDs** = disease modifying anti-rheumatic drugs, **DRM** = dose ranging multicenter, **MDBC** = multicenter double blind parallel, **wks** = weeks.
integrin have a potential role in the therapeutics of RA. Echistatin is another molecule under development.

**Anti Interleukins in Critical Pathological Conditions**

**Bronchial Asthma:** Accumulation of eosinophils in the bronchial mucosa of individuals with asthma is considered to be a central event in the pathogenesis of asthma. Mepolizumab is a humanized anti–IL-5 monoclonal antibody. In animal models, airway eosinophil recruitment and airway hyperresponsiveness in response to allergen challenge are reduced by specific targeting of IL-5. However mepolizumab treatment does not appear to add significant clinical benefit in patients with asthma with persistent symptoms despite inhaled corticosteroid therapy.

In a clinically relevant model of chronic allergic asthma in mice neutralizing antibodies to IL-13 effectively suppressed eosinophil recruitment and accumulation of chronic inflammatory cells in the airways. It also partially suppressed changes of airway wall remodeling, including goblet cell hyperplasia/metaplasia and subepithelial fibrosis, but had limited ability to inhibit airway hyperreactivity (AHR). However, treatment with anti–IL-13 resulted in a significant clinical benefit in patients with asthma with persistent symptoms despite inhaled corticosteroid therapy.

**Crohn’s disease** Crohn’s disease is characterized by increased production of IL-12 by antigen-presenting cells in intestinal tissue and interferon-γ and TNF-α by intestinal lymphocytes and macrophages. Anti–IL-12 monoclonal antibody therapy induces clinical response and remission in patients with active Crohn’s disease. In a clinical trial 79 patients with active Crohn’s disease were randomized to receive seven weekly subcutaneous injections of anti–IL-12 human monoclonal antibody (1 mg/kg body weight or 3 mg/kg body weight) or placebo, in an interrupted (one-month span after first dose, n = 40) or continuous regimen (n = 39). Continuous weekly therapy with 3-mg/kg anti–interleukin-12 resulted in significantly higher response rates at seven weeks compared with placebo.

**Acute respiratory distress syndrome:** Anti–IL-8 antibodies are high in patients of acute respiratory distress syndrome and molecules targeting them can be of potential help in these patients. Septic shock: Patients with septic shock have T cell hyporesponsiveness and immune suppression, which, if persistent, are associated with increased mortality. In the murine cecal ligation and puncture (CLP) model of sepsis, it has been reported that early treatment with the anti-inflammatory cytokine IL-10 delays the onset of irreversible shock.

**Cytokine targets in preclinical development**

Interferon (IFN)-γ blockade using a polyclonal anti-IFN-γ antibody has been shown to produce suppression of RA disease activity in a small RCT. Suppression of IL-17, anti-IL-18 antibody and the inhibition of IL-18 secretion via inhibition of caspase 1or antagonism of the proinflammatory purinergic receptor P2X7 are other approaches under development. Several adipokines (adiponectin) have been shown to modulates TNF-induced inflammation. Resistin is a cysteine-rich secretory protein originally implicated in insulin resistance and atherogenesis. It is expressed at high levels in RA synovial tissues, can promote TNF and IL-6 release. Therapeutic targeting of resistin offers the potential to modify not only local inflammation, but also the systemic insulin resistance that is characteristic of RA and other chronic inflammatory conditions.

A number of biological agents are being studied actively at the present time and it is hoped that they may generate novel therapies for and a greater understanding of immuno-inflammatory diseases (Table-3). The future for immunomodulatory intervention in rheumatology looks very promising. Greater understanding of the intricacies of the immune response that underlie the disease should continue to yield viable, specific targets for novel therapies. Advances in biopharmaceuticals should generate treatments that maximize efficacy while minimizing toxicity. These novel therapeutic agents could give new hopes to the clinician truly to modify the disease and achieve tangible improvements in the lives of the patients.

**References**

1. Mehlis S, Gordon KB. From laboratory to clinic: Rationale for biologic therapy. Dermatol Clin 2004;22:371-7.
2. Dogra A, Sachdeva S. Biologic therapy in psoriasis. Indian J Dermatol Venereol Leprol 2006;72:256-65.
3. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial
infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 2003;42:617-21.

4. McNees IB, Liew FY. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:31-9.

5. Pontikaki I, Gerloni V, Gattinara M, Luriati A, Salmaso A, De Marco G, et al. Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo 2006;58:31-8.

6. Feldmann M, Miotla J, Paleolog E, Williams R, Malffait AM, Taylor P, et al. Future prospects for anti-cytokine treatment. Ann Rheum Dis 2000;59:i119-22.

7. Cytokines mediating inflammatory and effector functions. Available from: http://www.nic.sav.sk/logos/books/scientific/node32.html. [last assessed on 2006 Dec 10].

8. Antibodies from IMGENEX: Cytokine and Chemokine http://www.imgenex.com/CytokineChemokine.php - 87k. [last assessed on 2006 Dec 10].

9. Ken JB. Biologic therapies in Rheumatoid arthritis. Curr Rheu Rep 1999,1:157-63.

10. Sharma R, Verma U. A novel therapeutic approach in rheumatoid arthritis. Ind J Pharmacol 2005;36:265-6.

11. Vila AT, Puig L, Fernandez-Figuera MT, Laiz AM, Vidal D, Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: Clinicopathological study of five patients. Br J Dermatol 2005;153:417-23.

12. Chau LS, Mok CC, Choy E. Non-tumor necrosis factor biological therapies for rheumatoid arthritis. Am J Rheumatol 2005;8:77-83.

13. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9:S136-43.

14. den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760-2.

15. National Institute of clinical excellence. Full guidance: Anakinra for rheumatoid arthritis. Technology appraisal Nov 2003. Available from: http://www.nice.org.uk/pdf/Tao72_guidance.pdf. [last assessed on 2004 Jun 24].

16. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:574-8.

17. Nuki G, Bresnihan B, Bear MB, McCabe D; European Group of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838-46.

18. Matsubayashi T, Sugihara H, Arai T, Oh-Ishi T, Inamo Y. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Paediatr 2006;95:246-9.

19. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther 2006;23:208-17.

20. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrery, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor-α inhibition. N Engl J Med 2005;353:1114-23.

21. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.

22. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.

23. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 2003;49:816-25.

24. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfiq NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;21:2004-13.

25. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized control trial. JAMA 2003;23:3073-80.

26. Leonard CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trials. J Am Acad Dermatol 2005;52:425-33.

27. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8.

28. Sundharam J. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Indian J Dermatol Venereol Leprol 2006;72:173-4.

29. FDA Approves Rituxan - The first targeted B-cell therapy for treatment of moderate-to-severe rheumatoid arthritis. Available from: http://www.leaddiscovery.co.uk/dailyupdates_alert_ MArch_1.html. [last assessed on 2006 Aug 16].
30. Gupta N, Srivastava A. Monoclonal antibodies: Targeted therapy. Indian J Pharmaco 2006;38:390-6.
31. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol (Oxford) 2001;40:205-11.
32. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol 1993;20:259-62.
33. Nishimoto N, Yoshizaki K, Maeda K, Kurtani T, Deguchi H, Sato B, et al. Toxicity, Pharmacokinetics and dose-finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis phase I/II clinical study. J Rheumatol 2003;30:1426-35.
34. Singh R, Robinson DB, Gabalawy HS. Emerging biologic therapies in rheumatoid arthritis: Cell targets and cytokines. Curr Opin Rheumatol 2005;2:38-43.
35. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005;28:231-8.
36. Chi Chiu MO. Biological therapies for rheumatoid arthritis: Beyond TNF-[alpha] blockade. Aplar J Rheumatol 2006;9:200-5.
37. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63:321-9.
38. Baslund B, Tvende N, Dansnesklod-Samsoe B, Larsson P, Panayi G, Petersen J, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum 2005;52:2686-92.
39. Zheng XX, Tvende N, Dansnesklod-Samsoe B, Larsson P, Panayi G, Petersen J. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003;19:503-14.
40. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Resp Critical care Med 2007; 176:1062-71.
41. Young G, Li L, Volk A, Emmell E, Petley T, Giles–Komar J, et al. Therapeutic dosing with anti interleukin-13 monoclonal antibody inhibits Asthma progression in mice. J Pharm Exp Ther 2005;313:8-15.
42. Anna K, James M BS, Ian SG. Colin R R, Christopher, Seamas D. Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Critical Care Med 2002;30: 2335-7.
43. Waknine Y. Anticytokine Therapy May Be Effective in Active Crohn's Disease. www.medscap.com, assessed on 24-12-2008.
44. Mollie OM, Mary A O, Alan DL, Samir Q L. Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome. BioMedical Press, Augusta, GA, ETATS-UNIS (1994) (Revue) www.cat.inist.fr. Assessed on 24-12-2008.
45. SigidinYA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 203–7.
46. KolisJK and LindenA. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467–76.
47. Lubberts E, Koenders MI, van den Berg WB. The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29–37.
48. Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer JM, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inß ammatory arthritis. Ann Rheum Dis 2004; 63: 1393–8.
49. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19: 641–4.
50. Schaffler A, Ehling A, Neumann E, Herfarth H, Turner I, Scholmerich J, et al. Adipocytokines in synovial fluid. JAMA 2003; 290: 1709–10.
51. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789–95.

Source of Support: Nil, Conflict of Interest: None declared.